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ABSTRACT:
The telomerase protein is constitutively activated in malignant cells from many patients 
with cancer, including the chronic myeloid leukemia (CML), but whether telomerase is 
essential for the pathogenesis of this disease is not known. Here, we used telomerase 
deficient mice to determine the requirement for telomerase in CML induced by BCR-
ABL in mouse models of CML. Loss of one telomerase allele or complete deletion of 
telomerase prevented the development of leukemia induced by BCR-ABL. However, 
BCR-ABL was expressed and active in telomerase heterozygous and null leukemic 
hematopoietic stem cells. These results demonstrate that telomerase is essential for 
oncogene-induced reprogramming of hematopoietic stem cells in CML development 
and validate telomerase and the genes it regulates as targets for therapy in CML.
INTRODUCTION
Activation of telomerase is associated with 
malignancy in many human cancers [1]. Telomerase 
inhibition was proposed as a potential cancer therapy 
when  telomere  shortening  was  first  described  in 
human cells [2]. Telomerase-deficient mice have been 
generated via deletion of the mouse terc gene encoding 
the RNA component of telomerase [3]. Terc-/- mice 
show phenotypic abnormalities only after successive 
generations of terc-/- intrecrosses [4, 5].  Strong evidence 
has accumulated that short telomeres limit tumor growth. 
Crosses of terc-/- mice to tumor prone models demonstrate 
that the short telomere response significantly limits tumor 
formation [6].  However, in contrast to these findings in 
differentiated tumor cells, the contribution of telomerase 
to the biology of cancer stem cells (CSC) has not been 
previously investigated.
Recently we have shown that the restricted 
expression of the BCR-ABL oncogene, linked to chronic 
myeloid leukemia (CML) disease, to the hematopoietic 
stem cell compartment is capable of generating a 
full-blown tumour with all its differentiated cellular 
components, showing a hands-off role for BCR-ABL in 
regulating CML formation [7-12]. BCR-ABL oncogene 
inactivation could not change this tumor reprogramming 
fate at the CSC level, in agreement with the common 
occurrence of tumor relapse by which human CML 
evolves to escape BCR-ABL pharmacological inactivation 
[13-22]. Thus, it seems important to know how to 
eradicate and/or prevent this BCR-ABLp210-induced 
reprogramming of stem cells [10-12]. In order to identify 
the genes that are associated with BCR-ABLp210-induced 
reprogramming of stem cells we performed a supervised 
analysis of the transcriptional profiles of CSCs purified 
from  Sca1-BCR-ABLp210 mice versus hematopoietic 
stem cells from control mice. The data identified that terc 
gene was expressed in CSCs in the Sca1-BCR-ABLp210 
mice, although it was not differentially regulated in 
CSCs versus control hematopoietic stem cells [7, 8]. 
Now, to assess the functional importance of telomerase 
and telomere status in this Sca1-BCR-ABLp210 model, 
the terc gene knockout was established in these Sca1-
BCR-ABLp210 mice, and tumor phenotype assessed 
in the first generation of telomerase heterozygous and 
homozygous mice. Remarkably, the data provide evidence Oncotarget 2012; 3:  261-266 262 www.impactjournals.com/oncotarget
that telomerase activity is essential for BCR-ABLp210-
induced reprogramming of stem cells. Overall, our results 
demostrate that telomerase plays a critical role in the 
pathogenesis of BCR-ABL-CML, and validate telomerase 
and the genes it regulates as targets for therapy in CML.
RESULTS AND DISCUSSION
In order to understand the role of telomerase in 
leukemia stem cell (LSC) generation and maintenance, we 
have taken advantage of our Sca1-BCR-ABLp210 mouse 
model of human chronic myeloid leukaemia (CML), a 
paradigmatic stem-cell disorder [23, 24]. This transgenic 
mouse was engineered to express the human BCRABLp210 
cDNA under the control of the Sca1 promoter in order to 
limit and determine the effect of ectopic expression of 
BCRABLp210 in hematopoietic stem/progenitor cells [7, 
8, 25, 26]. This model not only faithfully recapitulates 
the human disease but also has been able to anticipate 
that human CML stem cells survival is Bcr-Abl kinase 
independent and suggest curative approaches in CML 
must focus on kinase-independent mechanisms of 
resistance [7, 27, 28]. This model represents an ideal 
system to analyze the contributions of telomerase activity 
deficiency to the LSC biology and malignant progression 
of CML. To this end, terc-deficient mice were crossed 
to Sca1-BCR-ABLp210 mice to produce and analyzed 
cohorts of Sca1-BCR-ABLp210 ter+/- (n=17) and of Sca1-
BCR-ABLp210 ter-/- (n=17) experimental mice together 
with Sca1-BCR-ABLp210 ter+/+ (n=21) controls. Mice 
were monitored clinically and by serial peripheral blood 
count for evidence of CML for 20 months. As described 
[7], all Sca1-BCR-ABLp210 ter+/+ mice develop CML 
(Table I). Surprisingly, when the compound Sca1-BCR-
ABLp210 telomerase-deficient mice were analysed, CML 
was not found in the majority of them and the survival of 
these Sca1-BCR-ABLp210 ter+/- and Sca1-BCR-ABLp210 
ter-/- mice was significantly increased in comparison with 
Sca1-BCR-ABLp210 ter+/+ (Table I, Figure 1). Histologic 
analysis revealed only similar pathology to Sca1-BCR-
ABLp210 ter+/+ mice in 4 moribund Sca1-BCR-ABLp210 
ter+/- and 3 moribund Sca1-BCR-ABLp210 ter+/+ mice, 
respectively (Figure 2). On the contrary, the majority of 
old Sca1-BCR-ABLp210 ter+/- and Sca1-BCR-ABLp210 
ter-/- mice do not develop CML as evidenced by the 
normal spleen sizes and normal leukocyte cellularity in the 
peripheral blood. The absence of CML disease was further 
confirmed by histologic analysis that revealed normal 
spleen in majority old Sca1-BCR-ABLp210 ter+/- and Sca1-
BCR-ABLp210 ter-/- where we cannot detect the dramatic 
expansion of progenitors and differentiated myeloid cells 
that is characteristic of CML (Figure 1). Quantitative 
RT-PCR of BCR-ABLp210 messenger mRNA confirmed 
that  BCR-ABL  was  expressed  in  telomerase-deficient 
hematopoietic stem cells (Figure 3). These results indicate 
that the reduction in telomerase dosage in hematopoietic 
stem cells does interfere with the development of CML 
induced by BCR-ABL. 
Figure 1: Telomerase is required for CML development in Sca1-BCR-ABLp210 mice. Representative histologic appearance 
of spleen of old Sca1-BCR-ABLp210 ter+/-,  Sca1-BCR-ABLp210 ter-/-,  Sca1-BCR-ABLp210 ter+/+ and control wild-type mice after 
hematoxylin-eosin staining. Note the organ infiltration by myeloid cells in spleen and the presence of blasts and mature myeloid cells in 
Sca1-BCR-ABLp210 ter+/+mice.Oncotarget 2012; 3:  261-266 263 www.impactjournals.com/oncotarget
Overall,  our  work  demonstrates  for  the  first 
time that telomerase is required for the generation 
and maintenance of LSCs. These results demonstrate 
that telomerase is essential for oncogene-induced 
reprogramming of hematopoietic stem cells in CML 
development and validate telomerase and the genes it 
regulates as targets for therapy in CML. This evidence 
that telomerase inactivation could modify LSC indicates 
that the reduction/absence of telomerase does not have an 
instructive role in the genesis of tumor CML cells, but just 
a permissive one, preventing cells with damage from being 
successfully terminally reprogrammed. This indicates that 
the driving force of the reprogramming process is the 
BCR-ABL oncogene itself. However, targeting of BCR-
ABL does not affect CML stem cells. The search for ways 
to eliminate leukemic stem cells has became a priority 
due to their resistance to kinase inhibitors and the likely 
role they play in disease recurrence [29]. A number of 
strategies have yielded promissing results. Our results add 
the telomerase pathway as a potential therapeutic target 
whose inactivation can lead to CML stem cell eradication.
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MATERIALS AND METHODS
Ethics statement
All animal work has been conducted according to 
relevant national and international guidelines and it has 
been approved by the Bioethics Subcommittee of Consejo 
Superior de Investigaciones Cientificas (CSIC).
Mice 
The  Sca1-BCR-ABLp210 mice [7] and  terc gene 
targeted mice [3] have both been described previously. 
Southern blot-based genotyping for Sca1-BCR-ABLp210 
Figure 2: Some Sca1-BCR-ABLp210 ter+/- and Sca1-BCR-ABLp210 ter-/- mice develop CML. Representative histologic 
appearance of spleen of old Sca1-BCR-ABLp210 ter+/- Sca1-BCR-ABLp210 ter-/-, and control wild-type mice after hematoxylin-eosin 
staining. Note the organ infiltration by myeloid (blasts and mature) cells in spleen.Oncotarget 2012; 3:  261-266 264 www.impactjournals.com/oncotarget
[7, 30] and terc  [3], respectively, were performed 
as  described.  Heterozygous ter+/- mice were bred to 
Sca1-BCR-ABLp210 mice to generate compound 
heterozygotes. F1 animals were crossed to obtain null 
ter-/- mice  heterozygous  for  Sca1-BCR-ABLp210 mice. 
Tumor phenotype was assessed in the first generation of 
telomerase heterozygous and homozygous mice.
Histological analysis
All mice included in this study were subjected to 
standard necropsy. All major organs were examined 
under the dissecting microscope, and samples of each 
organ  were  processed  into  paraffin,  sectioned  and 
examined histologically. All tissue samples were taken 
by the pathologist from homogenous and viable portions 
of  the  resected  sample  and  fixed  within  2-5  min.  of 
excision. Hematoxylin- and eosin-stained sections of each 
tissue were reviewed by a single pathologist (T.F.). For 
comparative studies, age-matched mice were used.
Real-time PCR quantification
 cDNA for use in quantitative PCR studies was 
synthesized using reverse transcriptase (Access RT-PCR 
System; Promega, Madison, WI). Two µl of second round 
amplified RNA was transcribed. Primers and probes used 
for quantitative PCR are commercially available (TaqMan 
Assays-on-Demand Gene Expression Products, Applied 
Biosystems, Foster City, CA). In addition the probes were 
designed so that genomic DNA would not be detected 
during the PCR. The sequences of the specific primers 
and probes were as follow: BCR-ABLp210, sense primer 
5’-TTCTGAATGTCATCGTCCACTCA-3’,  antisense 
primer 5’-AGATGCTACTGGCCGCTGA-3’ and probe 
5´-CCACTGGATTTAAGCAGAGTTCAAAAGCCC-3’; 
c-Abl, sense primer 
5’-CACTCTCAGCATCACTAAAGGTGAA-3’, antisense 
primer 5’-CGTTTGGGCTTCACACCATT-3’, and probe 
5’-CCGGGTCTTGGGTTATAATCACAATG-3’. 
Analysis and monitoring of disease
Peripheral blood was collected from retro-orbital 
plexus with a heparinized capillary tube, and total white 
blood cell and differential counts were performed twice a 
week. The number of white blood cells was determined 
with a hemocytometer after lysis of enucleated red blood 
cells with RCLB lysis buffer (0.15 M NH4Cl; 1 mM 
KHCO3; 0.1 mM Na2-EDTA, pH 7.4).
Flow cytometry
Nucleated cells were obtained from total bone 
marrow (flushing from the long bones), peripheral blood, 
thymus, liver and spleen. In order to prepare cells for 
flow cytometry, contaminating red blood cells were lyzed 
with RCLB lysis buffer and the remaining cells were then 
washed in PBS with 2% FCS. After staining, all cells were 
washed once in PBS with 2% FCS containing 2 mg/mL 
Table I: Incidence of CML in Sca1-BCR-ABLp210 ter+/- and ter-/- mice.
Figure  3:  Quantification  of  Sca1-CR-ABLp210 
expression in Sca1+Lin- cells of Sca1-BCR-ABLp210 
ter+/- and Sca1-BCR-ABLp210 ter-/- mice. Quantification 
of BCR-ABLp210 expression in Sca1-BCRABLp210 ter+/- and 
Sca1-BCRABLp210 ter-/- mice by real-time PCR in Sca1+Lin- 








Mice with CML 4 3 21
Mice without CML 13 14 0
Total mice n=17 n=17 n=21Oncotarget 2012; 3:  261-266 265 www.impactjournals.com/oncotarget
propidium iodide (PI) to allow dead cells to be excluded 
from both analyses and sorting procedures. Monoclonal 
antibodies were obtained from Pharmingen and included: 
Lineage markers (CD45R/B220, for B lineage staining; 
CD4, CD8 and CD3 for T cell lineage; CD11b and Gr1 
for myeloid lineage and TER119 for erythroid lineage) and 
Sca1 (E13-161.7) for stem cells. Single cell suspensions 
from the different tissue samples obtained by routine 
techniques were incubated first with purified anti-mouse 
CD32/CD16 (Pharmingen) prior to the addition of other 
antibodies, to block binding via Fc receptors and then 
with an appropriate dilution of the different antibodies at 
room temperature or 4 oC, respectively. The samples and 
the data were analysed in a FACSCalibur using CellQuest 
software (Becton Dickinson). Specific fluorescence of 
FITC and PE excited at 488 nm (0.4 W) and 633 nm 
(30 mW), respectively, as well as known forward and 
orthogonal light scattering properties of mouse cells were 
used to establish gates. For each analysis a total of at least 
5.000 viable (PI-) cells were assessed.
Cell purification
For cell sorter separation, bone marrow cells were 
incubated with anti-Sca1 and anti-lineage markers 
antibodies (CD3, CD4, CD8, B220, TER119, Gr1, and 
Mac1). Sca1+Lin- and Sca1-Lin+ cells were isolated and 
highly purified from the BM of leukemic primary mice or 
control mice by fluorescence-activated cell sorting (FACS) 
(FACSVANTAGE;  Becton  Dickinson).  c-kit  (CD117) 
was not used for stem cell isolation as previous studies 
of human and mouse specimens have described down-
regulation of c-kit as a feature of leukemia stem cells [7]. 
Sorted cells were then re-analyzed for purity with the 
FACS and determined to be over 98%.
Statistical analysis
The X2 test was used to compare leukemia incidence 
in Sca1-BCR-ABLp210 ter-/- mice and Sca1-BCR-ABLp210 
ter+/- versus Sca1-BCR-ABLp210 and wild-type  mice. 
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